Overall survival outcomes in older patients with metastatic breast cancer: A National Cancer Database analysis.doi:10.1200/JCO.2023.41.16_suppl.120497433212049#Background:Over the last few decades, improvements in healthcare have increased life expectancy by nearly 10 years resulting in a rise ...
“induces cancer cell-selective death … in several human tumor xenografts and genetic mouse models of human breast cancer in vivo”; however, despite this encouraging preclinical efficacy, UVI5008 has not yet made it to the clinic and is, therefore, as previously mentioned, outside the sc...
“We are forging a new path for advanced metastatic breast cancer, a terminal disease with a very limited life expectancy of 6.7 to 9.8 months,” stated Dr. William V. Williams, BriaCell’s President and CEO. “The impressive survival benefit and tolerab...
Article 19 January 2022 Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer Article Open access 01 March 2023 Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer Article 20 July 2022 Introduction...
Close Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly. Email address Sign up I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy....
BriaCell highlights outstanding topline survival and clinical benefit data in advanced metastatic breast cancer at the 2023 SABCS. News release. BriaCell Therapeutics Corp. December 6, 2023. Accessed September 12, 2024. https://tinyurl.com/52ey3y9k Combination study of SV-BR-1-GM with ...
2023 and included data from 85 patients treated at 6 dose levels from 2.2 to 10.0 mg/kg. At the time of data cutoff, 80% remained on treatment. This data disclosure showed exciting preliminary activity with an ORR of 44.2% and DCR of 88.5%. Among HER2-positive breast cancer, the ORR ...
Brain metastases (BM) is a common complication, especially with advanced-stage melanoma. Melanoma accounts for almost 10 percent of BM and the third leading cause after lung and breast cancer.[11]In a large multi-institutional adjuvant study, the incidence of BM is about 15 percent in...
However, Cuq et al (2001) reported that UP overexpression did not increase the 5-FU sensitivity of human breast cancer cell. This discrepancy might be explained by species differences of UP expressions. Uridine phosphorylase increased in tumour tissues of mice and rats compared with human tissues,...
We propose a deep learning model - Probabilistic Prognostic Estimates of Survival in Metastatic Cancer Patients (PPES-Met) for estimating short-term life expectancy (>3 months) of the patients by analyzing free-text clinical notes in the electronic me